Literature DB >> 19213086

Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial.

Richard Gallo1, Steven R Steinhubl, Harvey D White, Gilles Montalescot.   

Abstract

OBJECTIVE: To evaluate the impact of sheath management on bleeding rates.
BACKGROUND: The procedural characteristics and anticoagulant regimen determine the frequency of postoperative bleeding complications following percutaneous coronary intervention (PCI).
METHODS: This subanalysis of the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial evaluated the relative impact of enoxaparin or unfractionated heparin (UFH) on the rate of non-coronary artery bypass graft-related major and minor bleeding, according to sheath management procedures in 3,528 patients undergoing elective PCI with a femoral approach.
RESULTS: Sheaths were removed at a median time of 54 min with enoxaparin 0.5 mg/kg, compared with 3 hr 14 min with enoxaparin 0.75 mg/kg and 2 hr 24 min with UFH. Early sheath removal (within 30 min from the end of PCI) was associated with reduced bleeding in patients receiving 0.5 or 0.75 mg/kg enoxaparin compared with UFH (enoxaparin 0.5 mg/kg: 4.9% vs. 10.8%; P < 0.001; enoxaparin 0.75 mg/kg: 5.0% vs. 10.8%; P < 0.001). Compared with UFH, major and minor bleeding was halved when enoxaparin (0.5 mg/kg and 0.75 mg/kg) was used in combination with a closure device (4.4% and 5.3% vs. 10.5% with UFH) or smaller (<7 Fr) sheath sizes (4.9% and 6.0% vs. 9.3%).
CONCLUSION: This analysis shows that early sheath removal can be performed safely following elective PCI in patients receiving enoxaparin. Enoxaparin use was associated with less major and minor bleeding compared with UFH, when either a closure device or a smaller sheath size was used. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19213086     DOI: 10.1002/ccd.21764

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  5 in total

Review 1.  Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?

Authors:  Ludovic Drouet
Journal:  Target Oncol       Date:  2012-01-25       Impact factor: 4.493

Review 2.  Achieving safe femoral arterial access.

Authors:  Michael S Lee; Jeremy Kong
Journal:  Curr Cardiol Rep       Date:  2015-06       Impact factor: 2.931

3.  Bleeding avoidance strategies. Consensus and controversy.

Authors:  Harold L Dauerman; Sunil V Rao; Frederic S Resnic; Robert J Applegate
Journal:  J Am Coll Cardiol       Date:  2011-06-28       Impact factor: 24.094

Review 4.  Administration of low molecular weight and unfractionated heparin during percutaneous coronary intervention.

Authors:  Sadegh Ali-Hassan-Sayegh; Seyed Jalil Mirhosseini; Azadeh Shahidzadeh; Parisa Mahdavi; Mahbube Tahernejad; Fatemeh Haddad; Mohammad Reza Lotfaliani; Anton Sabashnikov; Aron-Frederik Popov
Journal:  Indian Heart J       Date:  2016-01-26

5.  A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial.

Authors:  Thomas J Povsic; John P Vavalle; Laura H Aberle; Jaroslaw D Kasprzak; Mauricio G Cohen; Roxana Mehran; Christoph Bode; Christopher E Buller; Gilles Montalescot; Jan H Cornel; Andrzej Rynkiewicz; Michael E Ring; Uwe Zeymer; Madhu Natarajan; Nicolas Delarche; Steven L Zelenkofske; Richard C Becker; John H Alexander
Journal:  Eur Heart J       Date:  2012-08-02       Impact factor: 29.983

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.